Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 29

1.

A coding and non-coding transcriptomic perspective on the genomics of human metabolic disease.

Timmons JA, Atherton PJ, Larsson O, Sood S, Blokhin IO, Brogan RJ, Volmar CH, Josse AR, Slentz C, Wahlestedt C, Phillips SM, Phillips BE, Gallagher IJ, Kraus WE.

Nucleic Acids Res. 2018 Jul 9. doi: 10.1093/nar/gky570. [Epub ahead of print]

PMID:
29986096
2.

Vitamin C Sensitizes Melanoma to BET Inhibitors.

Mustafi S, Camarena V, Volmar CH, Huff TC, Sant DW, Brothers SP, Liu ZJ, Wahlestedt C, Wang G.

Cancer Res. 2018 Jan 15;78(2):572-583. doi: 10.1158/0008-5472.CAN-17-2040. Epub 2017 Nov 27.

PMID:
29180474
3.

Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study.

Swords RT, Azzam D, Al-Ali H, Lohse I, Volmar CH, Watts JM, Perez A, Rodriguez A, Vargas F, Elias R, Vega F, Zelent A, Brothers SP, Abbasi T, Trent J, Rangwala S, Deutsch Y, Conneally E, Drusbosky L, Cogle CR, Wahlestedt C.

Leuk Res. 2018 Jan;64:34-41. doi: 10.1016/j.leukres.2017.11.008. Epub 2017 Nov 11.

4.

Neuropeptide Y Y2 antagonist treated ovariectomized mice exhibit greater bone mineral density.

Seldeen KL, Halley PG, Volmar CH, Rodríguez MA, Hernandez M, Pang M, Carlsson SK, Suva LJ, Wahlestedt C, Troen BR, Brothers SP.

Neuropeptides. 2018 Feb;67:45-55. doi: 10.1016/j.npep.2017.11.005. Epub 2017 Nov 7.

PMID:
29129406
5.

M344 promotes nonamyloidogenic amyloid precursor protein processing while normalizing Alzheimer's disease genes and improving memory.

Volmar CH, Salah-Uddin H, Janczura KJ, Halley P, Lambert G, Wodrich A, Manoah S, Patel NH, Sartor GC, Mehta N, Miles NTH, Desse S, Dorcius D, Cameron MD, Brothers SP, Wahlestedt C.

Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):E9135-E9144. doi: 10.1073/pnas.1707544114. Epub 2017 Oct 9.

6.

An Ultra-High-Throughput Screen for Catalytic Inhibitors of Serine/Threonine Protein Phosphatases Types 1 and 5 (PP1C and PP5C).

Swingle M, Volmar CH, Saldanha SA, Chase P, Eberhart C, Salter EA, D'Arcy B, Schroeder CE, Golden JE, Wierzbicki A, Hodder P, Honkanen RE.

SLAS Discov. 2017 Jan;22(1):21-31. doi: 10.1177/1087057116668852. Epub 2016 Sep 27.

PMID:
27628691
7.

The BET-Bromodomain Inhibitor JQ1 Reduces Inflammation and Tau Phosphorylation at Ser396 in the Brain of the 3xTg Model of Alzheimer's Disease.

Magistri M, Velmeshev D, Makhmutova M, Patel P, Sartor GC, Volmar CH, Wahlestedt C, Faghihi MA.

Curr Alzheimer Res. 2016;13(9):985-95.

8.

Orphan diseases: state of the drug discovery art.

Volmar CH, Wahlestedt C, Brothers SP.

Wien Med Wochenschr. 2017 Jun;167(9-10):197-204. doi: 10.1007/s10354-015-0423-0. Epub 2016 Jan 27.

9.

The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation.

Pastori C, Kapranov P, Penas C, Peschansky V, Volmar CH, Sarkaria JN, Bregy A, Komotar R, St Laurent G, Ayad NG, Wahlestedt C.

Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8326-31. doi: 10.1073/pnas.1424220112. Epub 2015 Jun 25.

10.

Bromodomain inhibitors regulate the C9ORF72 locus in ALS.

Zeier Z, Esanov R, Belle KC, Volmar CH, Johnstone AL, Halley P, DeRosa BA, Khoury N, van Blitterswijk M, Rademakers R, Albert J, Brothers SP, Wuu J, Dykxhoorn DM, Benatar M, Wahlestedt C.

Exp Neurol. 2015 Sep;271:241-50. doi: 10.1016/j.expneurol.2015.06.017. Epub 2015 Jun 20.

11.

Helix 8 and the i3 loop of the muscarinic M3 receptor are crucial sites for its regulation by the Gβ5-RGS7 complex.

Karpinsky-Semper D, Tayou J, Levay K, Schuchardt BJ, Bhat V, Volmar CH, Farooq A, Slepak VZ.

Biochemistry. 2015 Feb 3;54(4):1077-88. doi: 10.1021/bi500980d. Epub 2015 Jan 20.

12.

Optimization and characterization of an antagonist for vasopressin 1a (V1a) receptor.

Mittapalli G, Abgaryan L, Brown SJ, Saldanha SA, Volmar CH, Ferguson J, Roberts E, Hodder P, Rosen H.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2013 Dec 11 [updated 2014 Sep 18].

13.

The BET bromodomain inhibitor I-BET151 acts downstream of smoothened protein to abrogate the growth of hedgehog protein-driven cancers.

Long J, Li B, Rodriguez-Blanco J, Pastori C, Volmar CH, Wahlestedt C, Capobianco A, Bai F, Pei XH, Ayad NG, Robbins DJ.

J Biol Chem. 2014 Dec 19;289(51):35494-502. doi: 10.1074/jbc.M114.595348. Epub 2014 Oct 29.

14.

Transcriptional repression of ER through hMAPK dependent histone deacetylation by class I HDACs.

Plotkin A, Volmar CH, Wahlestedt C, Ayad N, El-Ashry D.

Breast Cancer Res Treat. 2014 Sep;147(2):249-63. doi: 10.1007/s10549-014-3093-5. Epub 2014 Aug 17.

PMID:
25129342
15.

Differential effects of the Gβ5-RGS7 complex on muscarinic M3 receptor-induced Ca2+ influx and release.

Karpinsky-Semper D, Volmar CH, Brothers SP, Slepak VZ.

Mol Pharmacol. 2014 May;85(5):758-68. doi: 10.1124/mol.114.091843. Epub 2014 Feb 28.

16.

BET bromodomain proteins are required for glioblastoma cell proliferation.

Pastori C, Daniel M, Penas C, Volmar CH, Johnstone AL, Brothers SP, Graham RM, Allen B, Sarkaria JN, Komotar RJ, Wahlestedt C, Ayad NG.

Epigenetics. 2014 Apr;9(4):611-20. doi: 10.4161/epi.27906. Epub 2014 Feb 19.

17.

Characterization of an agonist probe for opioid receptor mu 1 (OPRM1)-opioid receptor delta 1 (OPRD1) heterodimerization.

Pinello C, Guerrero M, Eberhart C, Volmar CH, Saldanha SA, Cayanan C, Urbano M, Brown SJ, Ferguson J, Gomes I, Devi LA, Roberts E, Hodder P, Rosen H.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2012 Dec 17 [updated 2013 Apr 5].

18.

Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier.

Paris D, Bachmeier C, Patel N, Quadros A, Volmar CH, Laporte V, Ganey J, Beaulieu-Abdelahad D, Ait-Ghezala G, Crawford F, Mullan MJ.

Mol Med. 2011 Mar-Apr;17(3-4):149-62. doi: 10.2119/molmed.2010.00180. Epub 2010 Dec 17.

19.

CD40/CD40L interaction induces Abeta production and increases gamma-secretase activity independently of tumor necrosis factor receptor associated factor (TRAF) signaling.

Volmar CH, Ait-Ghezala G, Frieling J, Weeks OI, Mullan MJ.

Exp Cell Res. 2009 Aug 1;315(13):2265-74. doi: 10.1016/j.yexcr.2009.04.023. Epub 2009 May 5.

PMID:
19422822
20.

Diagnostic utility of APOE, soluble CD40, CD40L, and Abeta1-40 levels in plasma in Alzheimer's disease.

Ait-ghezala G, Abdullah L, Volmar CH, Paris D, Luis CA, Quadros A, Mouzon B, Mullan MA, Keegan AP, Parrish J, Crawford FC, Mathura VS, Mullan MJ.

Cytokine. 2008 Nov;44(2):283-7. doi: 10.1016/j.cyto.2008.08.013. Epub 2008 Oct 2.

PMID:
18835787

Supplemental Content

Loading ...
Support Center